GT200200081A - Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma - Google Patents

Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma

Info

Publication number
GT200200081A
GT200200081A GT200200081A GT200200081A GT200200081A GT 200200081 A GT200200081 A GT 200200081A GT 200200081 A GT200200081 A GT 200200081A GT 200200081 A GT200200081 A GT 200200081A GT 200200081 A GT200200081 A GT 200200081A
Authority
GT
Guatemala
Prior art keywords
triazatetraciclo
pharmaceutical compositions
same
pentaene
hexadeca
Prior art date
Application number
GT200200081A
Other languages
English (en)
Inventor
Philip James Johnson
Peter Robert Rose
Lewin Teophilus Wint
Glenn Robert Williams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200200081(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200200081A publication Critical patent/GT200200081A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LA PREPARACION DE SAL CITRATO DE 5,8,14TRIAZATETRACICLO [10.3.1.0 2,11.0 4,9]HEXADECA2(11), 3,5,7,9PENTAENO DE FORMULA (I) Y LAS COMPOSICIONES FARMACEUTICAS DE LA MISMA. ESTOS COMPUESTOS SON UTILES PARA UNA AMPLIA VARIEDAD DE PADECIMIENTOS TALES COMO INFLAMACIONES INTESTINALES, DEPRESION, TRASTORNOS DEL SUEÑO, DISFUNCION COGNITIVA, HIPERTENSION, ANOREXIA, BULIMIA, CEFALEA, ENTRE OTROS DESCRITOS EN EL EXPEDIENTE EN ESTUDIO.
GT200200081A 2001-05-14 2002-05-09 Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma GT200200081A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29086301P 2001-05-14 2001-05-14

Publications (1)

Publication Number Publication Date
GT200200081A true GT200200081A (es) 2003-04-22

Family

ID=23117854

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200081A GT200200081A (es) 2001-05-14 2002-05-09 Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma

Country Status (37)

Country Link
US (1) US6787549B2 (es)
EP (1) EP1390366B1 (es)
JP (1) JP4137645B2 (es)
KR (1) KR20040008175A (es)
CN (1) CN1509288A (es)
AP (1) AP1429A (es)
AR (1) AR035889A1 (es)
AT (1) ATE303386T1 (es)
BG (1) BG108344A (es)
CA (1) CA2446988A1 (es)
CZ (1) CZ20032917A3 (es)
DE (1) DE60205888T2 (es)
DO (1) DOP2002000390A (es)
DZ (1) DZ3503A1 (es)
EA (1) EA005529B1 (es)
EE (1) EE200300557A (es)
ES (1) ES2245731T3 (es)
GT (1) GT200200081A (es)
HR (1) HRP20030911A2 (es)
HU (1) HUP0304085A3 (es)
IL (1) IL157874A0 (es)
IS (1) IS6956A (es)
MA (1) MA27021A1 (es)
MX (1) MXPA03010365A (es)
MY (1) MY134123A (es)
NO (1) NO20035035L (es)
NZ (1) NZ528209A (es)
OA (1) OA12600A (es)
PA (1) PA8545001A1 (es)
PE (1) PE20021095A1 (es)
PL (1) PL366774A1 (es)
SK (1) SK13372003A3 (es)
TN (1) TNSN03112A1 (es)
UA (1) UA73421C2 (es)
UY (1) UY27287A1 (es)
WO (1) WO2002092597A1 (es)
ZA (1) ZA200307234B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286886B6 (sk) * 1997-12-31 2009-07-06 Pfizer Products Inc. Azapolycyklické zlúčeniny s anelovanou arylskupinou, ich použitie, farmaceutické kompozície na ich báze a medziprodukty
KR20040063975A (ko) 2001-11-30 2004-07-15 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]-헥사데카-2(11)3,5,7,9-펜타엔의 약학 조성물
CA2525874C (en) * 2003-05-20 2007-11-27 Pfizer Products Inc. Pharmaceutical compositions of varenicline
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
KR20090086071A (ko) * 2006-11-09 2009-08-10 화이자 프로덕츠 인코포레이티드 니코틴 중간체의 다형체
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
WO2009143347A2 (en) 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
MX2011006206A (es) * 2008-12-11 2011-07-20 S Bio Pte Ltd Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26- triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5 ,8,10,12(27),16,21,23-decaeno.
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
CA2801842A1 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
RU2012102052A (ru) 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
EP2837632B1 (en) 2012-04-13 2016-05-18 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Derivatives of triazabicyclo[3.2.1]octane useful for the treatment of proliferative diseases
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
EP3756653A1 (en) * 2019-06-28 2020-12-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Microparticulate varenicline citrate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286886B6 (sk) * 1997-12-31 2009-07-06 Pfizer Products Inc. Azapolycyklické zlúčeniny s anelovanou arylskupinou, ich použitie, farmaceutické kompozície na ich báze a medziprodukty
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
AP1429A (en) 2005-06-13
IS6956A (is) 2003-09-15
TNSN03112A1 (fr) 2005-12-23
NZ528209A (en) 2004-09-24
UY27287A1 (es) 2003-02-28
MA27021A1 (fr) 2004-12-20
DE60205888D1 (de) 2005-10-06
KR20040008175A (ko) 2004-01-28
DZ3503A1 (es) 2002-11-21
UA73421C2 (en) 2005-07-15
WO2002092597A1 (en) 2002-11-21
MY134123A (en) 2007-11-30
DOP2002000390A (es) 2003-03-15
JP4137645B2 (ja) 2008-08-20
NO20035035D0 (no) 2003-11-13
PA8545001A1 (es) 2003-09-05
US6787549B2 (en) 2004-09-07
NO20035035L (no) 2003-11-13
MXPA03010365A (es) 2004-03-16
ZA200307234B (en) 2004-09-16
HRP20030911A2 (en) 2004-02-29
CZ20032917A3 (cs) 2004-07-14
AR035889A1 (es) 2004-07-21
HUP0304085A2 (en) 2004-04-28
PL366774A1 (en) 2005-02-07
HUP0304085A3 (en) 2005-09-28
EP1390366B1 (en) 2005-08-31
US20030149091A1 (en) 2003-08-07
CN1509288A (zh) 2004-06-30
AP2002002522A0 (en) 2002-06-30
SK13372003A3 (sk) 2004-08-03
EA200301120A1 (ru) 2004-02-26
EE200300557A (et) 2004-04-15
ATE303386T1 (de) 2005-09-15
CA2446988A1 (en) 2002-11-21
JP2004529186A (ja) 2004-09-24
EP1390366A1 (en) 2004-02-25
ES2245731T3 (es) 2006-01-16
IL157874A0 (en) 2004-03-28
EA005529B1 (ru) 2005-04-28
OA12600A (en) 2006-06-09
DE60205888T2 (de) 2006-07-06
PE20021095A1 (es) 2002-12-14
BG108344A (bg) 2004-12-30

Similar Documents

Publication Publication Date Title
GT200200081A (es) Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
MXPA05009304A (es) Derivados de indol utiles para el tratamiento de enfermedades.
ECSP055615A (es) Nuevos compuestos de amida de ácido carboxílico con efecto antagónico de la hcm, medicamentos que contienen estos compuestos y procedimientos para su preparación
EP1725536B8 (en) Imidazoline derivatives having cb1-antagonistic activity
BG108207A (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
YU63703A (sh) 6-supstituisani pirido-pirimidini
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.
BRPI0409611A (pt) derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
MXPA05013059A (es) Derivados de 2-amino-piridina como agonistas del adrenoceptor beta-2.
BRPI0410649A (pt) benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k
WO2002102793A3 (en) Quinazolinediones as antibacterial agents
TW200505865A (en) Compounds useful for the treatment of diseases
GT200200280A (es) Lactamas como antagonistas de taquiquininas
MXPA05013210A (es) Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos.
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
WO2006029210A3 (en) Acyclic 1,3-diamines and uses therefor
BR0110255A (pt) Cromenilmetil pirimidinadiaminas como agentes antibacterianos
UA84300C2 (ru) ПРОИЗВОДНЫЕ ГЕКСА- И ОКТАГИДРОПИРИДО[1,2-a]ПИРАЗИНА С АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ОТНОСИТЕЛЬНО NK1
YU34604A (sh) Oligopeptidi kao inhibitori katepsina s i kompozicije koje ih sadrže
PA8558901A1 (es) Nuevos compuestos hexaciclicos
PE20030125A1 (es) PIRIDO[1,2-c]PIRIMIDINA COMO AGENTES ANTIBACTERIANOS